Prevalence of Diabetic Retinopathy and Dilated Fundus Examinations by Metropolitan Status from 2017-2021: An Assessment of the Behavioral Risk Factor Surveillance System.

Prevalence of Diabetic Retinopathy and Dilated Fundus Examinations by Metropolitan Status from 2017-2021: An Assessment of the Behavioral Risk Factor Surveillance System.

Publication date: Dec 18, 2024

Diabetic eye disease, namely diabetic retinopathy (DR), remains a leading cause of preventable blindness worldwide. Research has shown that treatment for diabetes and eye care was disrupted during the pandemic – with disparities between urban and rural populations being unknown. Thus, we aimed to assess the prevalence of reported rates of DR and dilated fundus exams from 2017 to 2021. We performed a cross-sectional analysis using data from the Behavioral Risk Factor Surveillance System (BRFSS). Among US residents with diabetes, we calculated the rates of DR and annual dilated fundus exams – overall and by metropolitan statistical area (MSA) – measuring differences using X tests. In 2017, the rate of DR was 19. 78% among US residents reporting diabetes, which increased to the highest rate in 2018 at 22. 19% before dropping to the lowest rates in 2019 and 2020 (18. 44%). These annual changes were statistically significant (p 

Concepts Keywords
Diabetes COVID-19
Ophthalmic diabetes
Rural diabetic retinopathy
Surveillance

Semantics

Type Source Name
disease MESH Diabetic Retinopathy
disease MESH eye disease
disease MESH blindness
disease MESH COVID-19

Original Article

(Visited 1 times, 1 visits today)